Elsevier

Oral Oncology

Volume 49, Issue 7, July 2013, Pages 702-706
Oral Oncology

Anaplastic thyroid cancer

https://doi.org/10.1016/j.oraloncology.2013.03.440Get rights and content

Summary

Purpose

Anaplastic thyroid cancer (ATC) is a lethal disease causing a global disproportionate number of thyroid cancer-related deaths. The American Thyroid Association (ATA) has recently produced clear and comprehensive guidelines to assist physicians treating ATC.

Methods

The recent ATA guideline publication was reviewed. A systematic review of studies indexed in Medline and Pubmed was also undertaken using search terms relevant to ATC.

Results

Patients with ATC have a median survival of 5 months and less than 20% survive 1 year. Early tumor dissemination results in 20–50% percent of patients having distant metastases and 90% having adjacent tissue invasion on presentation. This highlights the necessity for effective combined therapy. Stage IVA/ IVB, resectable disease may benefit from a multimodal (surgery, IMRT for loco regional control, and systemic therapy) approach. However, a majority of patients present with unresectable locoregional disease. Early palliative care involvement is inclusive of life-prolonging therapies. ATC management demands rapid, complex and integrated multidisciplinary decision making.

Conclusion

In this article we discuss the multidisciplinary strategies that exist to optimize the management of these patients in accordance with the recent guidelines from The American Thyroid Association.

Introduction

Anaplastic thyroid cancer (ATC) remains one of the most deadly diseases. It is responsible for 1.7% of all thyroid cancers in the United States, however geographical prevalence ranges from 1.3% to 9.8%. Overall patients have a median survival of 5 months and less than 20% survive 1 year.[1], [2]

The epithelial cancers of the thyroid include papillary, follicular, hurtle and anaplastic. These are divided into well differentiated thyroid cancers (WDTCs), poorly differentiated thyroid cancer (PDTC) and undifferentiated thyroid cancer (ATC). Internationally the prevalence of ATC has dropped due to improved management of WDTC and dietary iodine. A significant direction has been offered in the management of this disease with the publication of guidelines by the American Thyroid Association (ATA) taskforce on ATC.3 This is a positive step treating these difficult problems.

The American Joint Committee on Cancer (AJCC) has categorized ATC into Stage IVA, B & C. Stages IVA are intrathyroidal tumors, in Stage IVB the primary tumor has evidence of gross extrathyroidal extension and Stage IVC patients have distant metastases. The primary tumors are staged as T4. Since there are no established and effective treatments regimens, reported by any single institution or a group, we have elected to elaborate upon the current guidelines published by the ATA, for management of ATC. Despite the rarity of supportive prospective trials the ATA guidelines frequently make strong recommendations supported by expert opinions. We will consider the key recommendations within this article.

Section snippets

Pathogenesis

The cytological characteristics of this tumor show multinucleated cells with large bizarre nuclei and multiple atypical mitotic figures. There are no features of thyroid differentiation. These tumors have a marked degree of invasiveness, extensive necrosis and are characterized by the presence of spindle, squamoid, giant or osteoclast like giant cells with frequent admixtures of these cell types. The three histopathological patterns of growth (spindle, pleomorphic and squamoid) are not of

Presentation and diagnosis

An efficient and coordinated assessment of the ATC patient is required which demands a multidisciplinary approach. Patients frequently present with progressive airway compromise, and given the early recurrent laryngeal nerve palsy rates, surgeons should complete an airway and vocal cord assessment with fiber optic laryngoscopy. In patients with symptoms suggestive of recurrent laryngeal nerve (RLN), tracheal and or esophageal invasion, panendoscopy and bronchoscopy should be performed

Treatment strategy

A number of studies in the literature have attempted to identify prognostic factors in ATC. Factors which decrease disease-related mortality include age less than 60, tumor size less than 7 cm and less extensive disease on presentation.15 A study of 47 ATC patients’ reports tumor size greater than 5 cm, acute symptoms, leukocytosis and distant metastases were independent risk factors for poor outcome.16 Improved survival indicators include younger age on presentation, greater extent of surgery

Surgery

Recommendation No. 19 guides us through surgical intervention. Initial approach to Stage IVA or IVB disease is tumor resectability. Complete resection is associated with prolonged disease free survival and overall survival with or without adjuvant chemoradiotherapy.[19], [20], [21], [22] Gross resection, and not debulking, is the goal of surgery. This requires consideration of the structures which may be required for an R0/R1 resection and the morbidity and mortality associated with that.

Airway management

Management of the airway in ATC is always a controversial area of debate. Airway intervention is dangerous and many ask, even after successful tracheotomy is it worth the negative quality of life implications. Patients with acute airway symptoms may require tracheotomy, and in those circumstances a cricothroidotomy is advised for rapid airway entry. These cases, in the ATC setting require experienced Head and Neck surgeons and carry a high mortality rate. It may also be of assistance to first

Systemic therapy

Early ATC tumor dissemination and propensity for distant metastases highlights the necessity for effective systemic chemotherapy. There are many avenues of chemotherapeutic interest in the literature currently.

Conclusion

The ATA guidelines on ATC management is an excellent document. The panel should be commended for their clear and concise work.

This disease warrants rapid and effective multidisciplinary care. The patient’s overall clinical status and TNM stage of the tumor should be determined as soon as possible. Excellent communication with the patient and family is essential for education, a realistic expectation of outcome and informed consent prior to the onset of therapy. Patients with Stage IVA/IVB

Conflict of interest statement

None declared.

References (29)

  • K.A. Aldinger et al.

    Anaplastic carcinoma of the thyroid: a review of 84 cases of spindle and giant cell carcinoma of the thyroid

    Cancer

    (1988)
  • I. Sugitani et al.

    Prognostic factors and therapeutic strategy for anaplastic carcinoma of the thyroid

    World J Surg

    (2001)
  • M. Xing et al.

    BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer

    J Clin Oncol

    (2009)
  • P. Hou et al.

    Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer

    Clin Cancer Res

    (2007)
  • Cited by (0)

    View full text